UPDATE: Short-Seller Article on Ligand (LGND) is Silly, Underlying Strength Remains - Roth Capital

Lemelson Capital Makes Short Case Against Ligand Pharma (LGND)

Ligand Pharma (NASDAQ: LGND) is dipping lower following a new report from Lemelson Capital, which makes a short case for the stock. The following is from the 02+ page report:

A significant portion of Ligands business model is based on the goal of partnering with other pharmaceutical companies to commercialize and market its assets, and therefore a significant part of its revenue is based largely on payments made to the Company by partners for royalties, milestones and license fees.

Despite an entirely opaque future, the dwindling of critical revenue streams... More

LGD-6972 Could Drive Partnership; Roth Keeps Ligand Pharma (LGND) at 'Buy'

Roth Capital affirms its Buy rating and $92 target price on Ligand Pharmaceuticals (Nasdaq: LGND) following data from the Phase I study of glucagon receptor antagonist LGD-6972.

Analyst Joseph Pantginis commented, LGND believes these data suggest that the molecule is potentially a best-inclass glucagon receptor antagonist. We are... More

Ligand Pharma (LGND) Issues Positive Update on LGD-6972 Phase 1 in T2D

Ligand Pharmaceuticals (Nasdaq: LGND) announced data from a Phase 1 clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus, and also demonstrate a robust response on fasting plasma glucose after a single dose. LGD-6972 is Ligands novel glucagon receptor antagonist and these first-in-human data were presented at the American Diabetes Associations 74th... More